CJC-1134-PC
AssetAlso CJC-1134-PC Injection
Long-acting exendin-4 albumin conjugate that activates the glucagon-like peptide-1 receptor
- Stage
- Phase 2
- Modality
- Peptide
- Target
- Insulin/IGF-1 signalling
- 1
- Indication
- 1,357
- Trials
- 1
- Developer
Indications
1Type 2 diabetes
Phase 2, Terminated, NCT01514149, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials1,357
- Evidence for its targets3
- Competitors12
- Aging relevance2
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.